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Abstract
Background: Although the importance of detecting, treating, and controlling hypertension has been recognized for
decades, the majority of patients with hypertension remain uncontrolled. The path from evidence to practice contains many
potential barriers, but their role has not been reviewed systematically. This review aimed to synthesize and identify
important barriers to hypertension control as reported by patients and healthcare providers.
Methods: Electronic databases MEDLINE, EMBASE and Global Health were searched systematically up to February 2013. Two
reviewers independently selected eligible studies. Two reviewers categorized barriers based on a theoretical framework of
behavior change. The theoretical framework suggests that a change in behavior requires a strong commitment to change
[intention], the necessary skills and abilities to adopt the behavior [capability], and an absence of health system and support
constraints.
Findings: Twenty-five qualitative studies and 44 quantitative studies met the inclusion criteria. In qualitative studies, health
system barriers were most commonly discussed in studies of patients and health care providers. Quantitative studies
identified disagreement with clinical recommendations as the most common barrier among health care providers.
Quantitative studies of patients yielded different results: lack of knowledge was the most common barrier to hypertension
awareness. Stress, anxiety and depression were most commonly reported as barriers that hindered or delayed adoption of a
healthier lifestyle. In terms of hypertension treatment adherence, patients mostly reported forgetting to take their
medication. Finally, priority setting barriers were most commonly reported by patients in terms of following up with their
health care providers.
Conclusions: This review identified a wide range of barriers facing patients and health care providers pursuing hypertension
control, indicating the need for targeted multi-faceted interventions. More methodologically rigorous studies that
encompass the range of barriers and that include low- and middle-income countries are required in order to inform policies
to improve hypertension control.
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Introduction
Rationale
Hypertension (HT) is the leading global risk factor for mortality
worldwide, responsible for 13% of deaths globally [1]. However,
HT detection, awareness, treatment and control are low world-
wide [2] Hypertension control at the population level involves
several steps. First, those at risk must be identified [awareness].
Second, HT patients must be treated appropriately, whether with
medication, lifestyle changes, or their combination. Third, they
must be followed up to ensure that they are adhering to treatment
and their blood pressure is controlled [3]. These recommendations
are based on established research evidence yet their implemen-
tation in practice is suboptimal. Implementation can fail because
of an inability to surmount barriers that relate to the patient, the
health care provider, or the health system [4,5]. Each of these has
been subject to previous research but, to our knowledge, their role,
importance, and generalizability has not been examined system-
atically thus far.
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Barriers can be assessed indirectly by analyzing associations
between characteristics such as region, socio-economic status, age
or sex, or directly by asking stakeholders such as patients and
providers about barriers they face. Indirect analysis of associations
often involves non-modifiable characteristics and does not
elucidate the actual reasons for subgroup disparities. Therefore
we seek to address the gap in the literature by providing a
systematic literature review of HT barriers as reported by patients
and health care providers. Specifically, we go beyond much
previous research that focused on patient adherence as the major
barrier to blood pressure control. There is a need for a more
nuanced approach to understanding HT control, taking account
of complex interactions at different levels of care and the roles of
different stakeholders involved [6]. The conceptual frameworks
used in this work have been limited in scope and are often not
linked to theories that might explain processes of behavior change
designed to achieve optimal implementation and thereby HT
control.
Objectives
The aim of this paper is to systematically review the literature
on barriers reported by HT patients as well as population groups
at risk for HT [together referred to as patients from here on] and
health care providers [referred to as providers from here on] that
may impede optimal HT awareness, treatment, or follow up with a
health care provider (Figure 1). This review focuses on individual
level barriers, whereby barriers related to the health system are
addressed only as they are reported by individuals, whether health
care providers or patients. We included qualitative data to gain a
better understanding of which barriers are perceived to be
important from the patients’ and providers’ perspective, and
quantitative data to assess their prevalence and their clinical
importance.
Methods
Protocol and registration
Methods of the systematic review were specified in advance and
documented in a published protocol in the International
Prospective Register of Systematic Reviews (PROSPERO),
registration number CRD42011001617.
Behavior change theoretical framework
Definition of barriers. Barriers to HT control in this
systematic review were defined as any factor limiting the
performance of a required behavior by patients or providers [6]
to achieve recommended HT awareness, treatment (medication
and/or lifestyle) or follow up care. As indicated, non-modifiable
attributes such as age, race, and gender were not considered. In
keeping with best practice, we begin with a theoretical framework
that encapsulates the barriers and makes it possible to explore
mediating pathways and moderators [7]. The framework draws on
theories from implementation research [8] and behavior change
[9]. Michie (2004) proposes 12 subthemes for investigating the
implementation of evidence based practice (Figure 1), organized
under 3 main themes whereby a change in behavior requires a
strong commitment for change (intention barriers), the necessary
skills and abilities to perform the behavior [capability barriers],
and no health system constraints [9]. These frameworks were used
to organize patient and provider reported barriers, which where
adapted to the specifics of HT control following an initial scoping
review of qualitative studies. Barriers related to the health system
are addressed in this paper only as they pertain to individuals,
whether health care providers or patients.
Definition of themes. Capability barriers may relate to
the knowledge of behaviors required to achieve HT control, or the
capacity to perform these behaviors. Intention barriers relate
to attitudes or motivations towards actions necessary to achieve
Figure 1. Barriers to hypertension management, modified from Michie et al (2004) and Fishbein et al (2000).
doi:10.1371/journal.pone.0084238.g001
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control and may be mediated by several behavioral characteristics.
Health care system barriers may include barriers that are
external to patients’ or health care providers’ control [10]. These
include availability of resources [inputs], financing and affordabil-
ity, and the mode of delivery and acceptability of health services.
These barriers also extend beyond the healthcare system to the
wider health environment, and include other facilities required for
a healthier lifestyle. In addition, medication related barriers for
patients, such as side effects, were included under health system
barriers as they are also out of patients’ control (Figure 1).
Information sources and search
Studies were identified by searching electronic databases,
scanning reference lists of included articles and consultations with
experts in the field. No limits were applied with respect to
language and those in languages other than English were
translated. The search was applied to MEDLINE (1948 to
January, 2013), EMBASE (1980 to 2013 Week 09) and Global
Health (1973 to January 2013). An experienced librarian helped in
developing the search strategy to identify studies (table S1 in file S1).
Controlled vocabulary and keywords focused on ‘‘hypertension’’,
‘‘barriers’’, and ‘‘obstacles’’. No limits to study design were
imposed.
Eligibility criteria and study selection
Table 1 shows the eligibility criteria for studies. Two reviewers
independently assessed studies identified by the search for
eligibility based on the title and abstract. Selected full text papers
were then assessed independently by the two reviewers using a
standardized form that was piloted on 6 studies designed to
describe the characteristics of studies to be included based on
recommendations in the Cochrane Handbook section 5.1.0 [11].
Disagreement was resolved by a third author. Unweighted kappa
for the second screening phase was calculated using PC-AGREE
software (version 2.5) to assess agreement between the 2 reviewers
and revealed an excellent agreement beyond chance of 0.87
(60.09) [11].
Data collection and data items
Two reviewers independently extracted data from included
studies using a form that was piloted on 4 randomly included
studies. The following information was extracted from each study:
Study characteristics [qualitative or quantitative design, overall
objective, setting, participant characteristics], barriers assessed in
the study, information on use of theory or validated tools to assess
barriers, prevalence of reported barriers, outcome measures (effect
of barrier on adherence to medication) when available.
Study quality assessment
Risk of bias was assessed at the study level. Following the
Cochrane Collaboration’s recommendation to present potential
biases for each study instead of using scores to rate quality, a set of
quality appraisal items relevant to the type of studies included was
applied (tables S3 and S4 in file S1). Quality of included qualitative
studies was assessed using an existing framework and its set of
validated tools [12]. This framework was selected for this review
due to its applicability among the different types of included
studies and ease of presentation. For quantitative studies, these
included biases in sample selection, quantification of barriers,
measure of the outcome, and appropriateness of statistical analysis
i.e adjusting for confounders when applicable.
Data synthesis and analysis
Studies were classified as qualitative or quantitative based on
authors’ description, and were organized according to the
theoretical framework separately for patients and providers.
Qualitative data investigates why and how certain barriers affect
the outcome of interest [13]. Consequently we used these data to
modify and explain themes according to the framework. We then
used quantitative data to quantify how common these barriers
were. Classification of barriers into the framework’s subthemes
was done independently by two reviewers; discrepancies were
resolved by a third reviewer.
Qualitative data analysis. Results from qualitative studies
were analyzed using descriptive analysis reporting in how many
Table 1. Eligibility criteria.
Types of participants:
Patient populations of any age, with a HT diagnosis or at risk for HT.
Health care provider populations were considered without restrictions to the type of health care provider [physician, nurse, other], level of practice [primary care vs.
hospital level], or the population they cater to.
Study outcome/focus
HT awareness; detection, screening.
HT treatment: Medication intake, medication adherence, clinic visits
Lifestyle change: diet, physical activity, alcohol intake, weight loss
Follow up with a health care provider for HT management
Clinical guideline adherence, medication prescription
Studies that focused on BP control in general, without specifying an outcome leading to control as specified above were excluded.
Types of studies:
Qualitative and quantitative observational studies assessing barriers to HT awareness, treatment (medication and lifestyle), or follow-up care. Effectiveness (RCT) and
comparison (cohort, case-control) studies were included only if a barrier assessment was assessed within the study.
Studies were included regardless of study quality
No language or publication date restrictions were imposed.
Conference abstracts and non- peer review studies were excluded.
doi:10.1371/journal.pone.0084238.t001
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studies barriers of the framework domains arose, with specific
examples of barriers to clarify the domains.
Quantitative analysis. Once barriers from each quantitative
study were organized into the framework, the proportion of
participants reporting each barrier was extracted [when reported].
This generated a measure of how frequently each barrier was
reported and facilitated identification of barriers that might be
inadequately studied in the literature, in the same way that was
done in a previous study of barriers and facilitators of adherence to
treatment for highly active antiretroviral therapy (HAART) [14],
showing the number of studies assessing each barrier. The
extracted proportions were then pooled in order to identify how
prevalent these barriers were across the different study populations
included in this review. When the same study had more than one
question or statement assessing the same barrier, the median
prevalence was calculated. This was done in order to prevent
pooling of duplicate results from the same study, which would
result in an overestimation of the pooled proportion [15].
The inverse variance method was used to pool proportions
presented in each study. Review manager 5 was utilized to
conduct these calculations. The proportion of study participants
reporting the barrier (p) and the study sample size were used to
calculate the standard error (SE(p)), using the following formula:
SE (p) = sqrt ((p)(1-p)/n [12].
Summary measures and additional analyses
Association measures for barriers with the outcome of interest
were also pooled and stratified by the frameworks subthemes. Four
of the five studies that provided effect measures used odds ratios,
the remaining study used hazard ratios [16]. Risk was assumed
similar for these two measures and they were pooled together,
sensitivity analysis was conducted by excluding the study reporting
hazard ratios. Only adjusted effect measures were pooled.
Due to expected heterogeneity in the included studies the
random effects model was used to pool the data, making an
adjustment to the study weights according to the extent of
variation of proportions from each study. Using a random effects
model does not explain or justify heterogeneity, yet it provides
wider confidence intervals [11]. Pooled proportions and pooled
effect measures are presented using forest plots depicting the 95%
confidence interval, the I2 statistic, and the number of pooled
studies. The I2 statistic describes the percentage of the variability
in effect estimates that is due to heterogeneity rather than sampling
error (chance) [11].
Results
Study selection
The search identified a total of 1,978 articles (Figure 2). Of these,
1,808 articles were excluded in the 1st screening based on title/
abstract reviews. The full texts of the remaining 170 citations were
examined in more detail in the 2nd screening, of which 69 studies
(25 qualitative, 44 quantitative) were included in the review. Three
included studies were translated from Russian [17], Portuguese
[18], and Korean [19] into English.
Study characteristics
Eight qualitative and 13 quantitative studies reported provider
barriers. Fifteen qualitative and 27 quantitative studies reported
patient barriers. Two qualitative and 4 quantitative studies
reported both patient and provider barriers. Table 2 presents a
summary of study characteristics. The majority of studies were
conducted in high income countries (HIC), mainly in the USA,
with only 14 (20%) in lower or middle income countries (LMIC).
Among patient studies, 28% were population based, while the
remaining studies recruited patients from clinic or hospital settings.
Among providers, 33% (n= 7) included non-physician health care
workers in their sample (nurses, pharmacists, social workers…)
(tables S2 and S3 in file S1).
Study quality
Risk of bias for each study is presented in tables S4 and S5 in file
S1. For qualitative studies, only 1 of the 25 studies explicitly
assessed the likely impact of the authors own personal character-
istics on the data obtained (reflexivity). The context or setting of
the study was inadequately described in 40% (n= 10) of studies,
and 68% (n= 17) of studies failed to support their methods or
results by a theoretical framework or a wider body of knowledge.
As for quantitative studies 84% (n= 37) reported a response
rate lower than 85%, and 68% (n= 30) did not use a validated
tool/instrument to assess barriers.
Results of Individual Studies and Synthesis of
Results
Table S6 in File S1 presents the number of qualitative studies in
which barriers were reported, according to the framework.
Provider reported barriers in qualitative studies
Capability barriers. Knowledge barriers were discussed in
two studies that were conducted by the same group [20,21];
providers reported that lack of knowledge regarding HT
management was not a barrier to HT control but there were
reports of unfamiliarity in how best to manage certain subgroups
like the elderly with comorbidities. Skills barriers mainly included
difficulty in keeping up with new clinical information [20],
educating and counselling patients [22] and addressing prehyper-
tension [23].
Intention and determinants of intention strength.
Motivation barriers pertained to the intention to perform the
action. Providers reported the difficulties and repeated failures in
addressing healthy behaviors and achieving a controlled blood
pressure resulting in lack of motivation to try [22–24]. Beliefs
about consequences related to concerns about medications,
clinical guidelines, and other recommendations. Providers doubted
the efficacy of certain medications [25] or were reluctant to initiate
aggressive anti-hypertensive drug treatment due to possible side
effects [24]. Some providers doubted whether following clinical
guidelines would improve outcomes [26]. Providers raised concerns
about the accuracy and representativeness of individual BP readings
during the visit as well as concerns regarding white coat effect when
taking these readings [20,21]. Breaking habit was another
barrier, where providers reported satisfaction with their current
performance [26], suggesting reluctance to change their habits or
routines [clinical inertia].
Social influence barriers included lack of care coordination
with colleagues as well as social pressure and conflicting roles in a
practice. Providers described their reluctance to initiate treatment
for ‘someone else’s patient’ despite repeated recording of high BPs
[21]. Poor coordination between different general practices and
lack of consensus in standardization of measurements were also
reported [20,23,27]. Problems with Priority setting may
sometimes prevent better HT control. For example, other acute
medical conditions competed for attention with HT during the
visit [26,27] making it harder to prioritize HT care. Professional
identity was commonly discussed in terms of lack of trust in the
evidence on which guidelines were based upon [21,26]. Providers
also reported that guidelines may not always be practical and do
Barriers to Hypertension Management
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not necessarily translate to everyday [24]. One study invoked
beliefs about capabilities, suggesting that providers cannot
perform according to the guidelines [26]. Emotional barriers,
which may include issues relating to stress or burn-out due to high
workloads, or to anxiety/depression, and Memory and atten-
tion barriers were not reported by providers.
Figure 2. Flow diagram of included studies.
doi:10.1371/journal.pone.0084238.g002
Table 2. Study characteristics (n = 69).
Number of studies
Qualitative Quantitative Total
High income countries
USA 15 22 37
UK 2 2 4
Canada 0 3 3
Other1 5 6 11
Middle and lower income countries2 3 11 14
Study setting
Primary/secondary care 19 35 54
Community 6 9 15
Study type
Focus groups 16 NA 16
In depth interviews 7 NA 7
Focus groups and interviews 2 NA 2
Cross sectional NA 41 41
RCT baseline NA 1 1
RCT follow up NA 2 2
Study population
Only hypertensive patients 12 26 38
Other chronic disease patient or general community 5 5 10
Physicians only 3 11 21
Other health care workers [nurses, pharmacists…] 5 2
TOTAL 25 44 69
1 Australia, Republic of Korea, Israel, Netherlands, Kuwait, Switzerland, Ireland, Singapore, Europe, Croatia.
2 qualitative studies: India, South Africa, Brazil, Malaysia, Nigeria, Trinidad & Tobago, China, and Russian Federation.
NA=No studies Available.
doi:10.1371/journal.pone.0084238.t002
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Health systems related barriers. Health system barriers were the
most commonly reported barriers among providers. Those
relating to Availability of health care resources included lack
of consultation time [22,23] which may impair the ability to follow
guidelines, resulting in poor BP control. Lack of space, equipment,
and shortage of staff were also reported [22]. In atypical settings,
disruption of treatment due to severed supply channels and
inoperable pharmacies following disasters were also reported [28].
Providers also reported difficulties in locating guidance on
delivering care [21,22]. Affordability barriers included insuffi-
cient financial reimbursement or incentives to apply recom-
mended HT care [21,23,24,26,27]. None of the providers
reported any barriers regarding providers’ acceptability of
health care or medications.
It is important to note that provider-focused studies also
reported the patient to be a barrier to guideline adherence; for
example providers stated that patients were reluctant to take more
medications [21] and they wanted to try changing their lifestyle
before starting drug therapy [21], thus creating a barrier for
providers seeking to follow clinical guidelines. Providers also
reported patients’ resistance to change to a healthier lifestyle, as
well as patient stress and comorbidities [26] as a barrier to BP
control. Since these barriers were patient-specific and are external
to providers they were not coded under provider barriers.
Patient reported barriers in qualitative studies
Capability barriers. Knowledge of HT risk factors varied
by study and within study; some participants were aware that a
poor diet, high salt and fat intake, and lack of physical activity
might be a risk factor for HT [29], whereas others reported less
knowledge of such risk factors [25,29]. Smoking and alcohol were
reported as risk factors in one study only [18]. Patients were not
familiar with blood pressure readings and their meaning [30].
Gaps in understanding risk factors to and consequences of HT
were reported [18,25,29–32]. Patients reported the need for better
education regarding HT management and prevention [29,30,33],
and suggested that, in comparison with HT, they receive more
information regarding diabetes [34]. In one study, not knowing
about the existence of screening service was reported as a barrier
to awareness [35]. Skills were discussed in terms of communi-
cation between patients and providers, such as not feeling guilty
about asking questions and knowing what questions to ask [36].
Lack of skills to check blood pressure at home were also discussed
[30].
Intention and determinants of intention strength.
Motivation barriers refer to intention to change and were
reported in terms of exercise, where patients described being too
lazy or too tired to exercise [37]. Lack of motivation was also
reported in terms of medication adherence, where patients
admitted to not putting enough effort or thought to taking their
medication as prescribed [34]. Beliefs about consequences of
taking medication were commonly discussed; participants believed
that they did not need anti-hypertensive medication because they
have no symptoms [36,38], they denied the diagnosis and viewed it
as a reaction to stressful events and not necessarily a chronic
disease [34]. Patients also expressed fear of ‘‘dependence’’ on anti-
HT medications if they continue to take them [36,39] and
preferred modifying their lifestyle over taking medication [40].
Beliefs about the consequences of a healthy lifestyle were also
discussed [31], African American patients, for example, were
reported as considering HT as being inevitable [41], similarly
some patients showed a fatalistic perspective suggesting that ‘‘it’s
all in God’s hands’’ [33]. Therefore improving diet or exercising
might not make any difference. Breaking habit barriers were
mostly reported in terms of adapting to a healthier lifestyle,
whereby patients mainly expressed difficulty in changing dietary
habits [22,33]. Difficulties with making long term medication
adherence a habit were also identified [25,36,37].
Social influence was reported as both a barrier and a
facilitator of improved HT control. Lack of social support, mainly
from the family, affected medication adherence [25,36] and
changing lifestyle [37]. Studies also reported that having to cook
for oneself differently from the rest of the family was perceived as a
barrier [22,31,37,41]. In terms of utilizing health care serves and
screening for HT, participants suggested that sessions aimed at
increasing health awareness should include groups of patients and
be social [35]. Social pressure was also reported as a barrier to a
healthier lifestyle [33,40]. Prioritizing one’s health was also
reported as a barrier. Participants found it hard to prioritize clinic
visits, diet and exercise over needs of family members
[22,34,38,40–42] and over work [35,37,42]. Patients reported
that stress and anxiety may affect HT management; such
emotions maybe related to lack of money and jobs, single
parenting, and living in unsafe neighbourhoods [31,34,37,39,41].
Memory or forgetting to take one’s medication appeared to play
an important role in medication adherence [30,36]. Beliefs
about capabilities were not discussed in any of the included
studies.
Healthcare system barriers. Availability barriers were
relevant to lifestyle change as well as medical treatment. Patients
reported lack of facilities, bad weather, and safety issues as barriers
to physical exercise [33,37]. Barriers to following a healthy diet
included absence of nearby stores that sell healthy foods [39],
limited healthy food choices when eating out [22], and lack of
guidance and dietary counselling from clinicians [30]. In terms of
utilizing care, patients reported difficulties with transportation
[29], inappropriate hours for screening services that conflict with
working hours [35], and difficulties in getting clinic appointments
[36], or absence of or inaccessible health care facilities [25,33].
Other availability barriers included transportation difficulties
hindering medication refills [30,42], no interpreter services in
physician offices [29], lack of information targeting population
subgroups such as African Americans [41], or short duration of
physician consultations [25].
Affordability of care barriers included lack of insurance and
high costs of treatment [30,38,40] resulting in patients seeking care
only for acute problems [25,28,29,37,41,42]. Cost issues also
limited the ability to follow a healthy diet [31,37,41] and to
exercise [33]. Acceptability of available care included poor
provider-patient communications [36], patients’ distrust in the
services provided [33,42], lack of respect for the poor [25], and
lack of attention to minorities [30,42]. Medication related
barriers mainly included side effects experienced due to anti-HT
medications [34,36–39], as well as dosing frequency, taste, and
large pill size [36].
Provider reported barriers in quantitative studies
Figure 3 presents the pooled prevelence of barriers reported by
providers from 13 studies [32,43–54]. In terms of capability
barriers, 19% (95%CI: 11–27%) of providers reported that their
lack of skills contributed to suboptimal BP control. 17% (95%CI:
7–27%) reported either directly or indirectly (by means of some
measure of their knowledge) lack of knowledge as a barrier. Belief
that one’s capabilities to manage and control HT were limited was
the most common of Intention barriers (49% of providers),
though it was only assessed in one study. This was followed by
social influence from peer providers (38%, 95%IC: 29–46%) and
providers’ disagreement with guidelines (36%, 95%IC: 17–56%).
Barriers to Hypertension Management
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In terms of health system barriers, low salaries and lack of
reimbursements were most often reported as barriers among
providers (65%, 95CI: 58–72%).
Patient reported barriers in quantitative studies
Figure 4 presents the pooled prevalence of barriers to each HT
management outcome organized by subthemes of the framework.
Four studies reported barriers to hypertension awareness
(figure 4.1) [55–58], 10 studies reported barriers to lifestyle change
(figure 4.2) [44,45,59–66], 15 studies reported barriers to
treatment adherence (figure 4.3) [16,43,58–60,67–76], and 9
studies reported barriers to following up with a health care
provider (figure 4.4) [44,58,59,62,65,73,77–79].
Of the 2 capability subthemes, only knowledge was assessed,
and was mostly reported as a barrier to HT medication treatment
adherence, reported as a barrier by 46% (95%CI:24–64%) of
patients. In terms of Intention barriers, memory and attention
barriers were of most importance to patients in terms of
medication adherence (55%, 95%CI:35–75%). In terms of
changing lifestyle, stress/anxiety was mostly reported (34%,
95%CI: 27–40%), but results were based on one study only.
Priority setting (27%, 95%CI: 12–42%) and breaking habit (27%,
95%CI: 9–45%) were more commonly assessed and also appeared
to be prevalent barriers to lifestyle change. Priority setting was
again the most commonly reported barrier to HT screening and
follow up with a provider (38%, 95%CI:32–44%). As for health
care system barriers, availability (29%, 95%CI:17–41) of
medication and its side effects (29%, 95%CI: 9–49%) were the
most common barriers to patients’ medication treatment adher-
ence and persistence. For seeking HT screening, affordability
barriers (28%, 95%CI: 2–53%) were more commonly reported
than availability barriers. And finally in terms of following up with
a provider, availability barriers had the highest prevalence (33%,
95%CI:9–58%).
Clinical importance of barriers
None of the provider studies reported measures of association of
barriers with guideline adherence. Therefore, it is not possible to
assess to what extent the provider reported barriers were actually
associated with worse care. For patients, it was possible to assess
the association of barriers with HT treatment adherence based on
5 studies that provided an adjusted effect measure [16,59,66,
67,69,74]. Figure 5 shows that overall reporting of at least one
barrier was associated with an increased risk of non-adherence
(OR: 1.27, 95%CI: 1.00–1.58). Heterogeneity was very high
(I2 = 78%), and excluding the one study that reported hazard
ratios instead of odds ratios did not explain heterogeneity
(OR=1.28, 95%CI: 1.03–1.60), 12 = 80%.
Stratifying the barriers by subthemes of our framework
explained most of this heterogeneity. Only one study reported a
measure for capability barriers, suggesting a non-statistically
increased risk of non-adherence among those with lower HT
Figure 3. Pooled prevalence (%) and 95% confidence intervals (CI) of provider level barriers to hypertension management
organized by Michie et al framework (n=13).
doi:10.1371/journal.pone.0084238.g003
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knowledge. Data was available on only 2 of the intention
subthemes and suggested a non-statistically significant trend
towards higher non-adherence among patients reporting barriers.
Finally, all 4 health systems subthemes were assessed in terms of
their effect on non-adherence, 3 of which [availability, affordabil-
ity, acceptability] indicated a non-statistically significant trend
towards higher non-adherence among patients reporting barriers.
Patients reporting medication side effects had a statistically
significant two fold increased risk of non-adherence (OR: 1.92,
95%CI: 1.47–2.49, I2 = 0%).
Comparison between health system barriers in HIC and
LMIC
Provider barriers. Only 3 studies reported qualitative data
from LMIC [India [25], Brazil [80], and South Africa [22]].
Differences with HIC appeared mainly in terms of availability
barriers; providers in LMIC reported shortages of space,
equipment and staff [22,25]. These barriers were not reported in
HIC. These differences were also observed in data from the 4
quantitative studies conducted in LMIC (Nigeria [45], Russian
federation [17], Trinidad [48] and China [52]). These studies were
more likely to assess and report lack of equipment, medication,
time [48], and specialists [17]. The studies from HIC focused
more on issues relating to availability of guidelines [46] and
organization of follow up care [43].
Patient barriers. Qualitative studies of patients in HIC
focused on lack of exercise facilities and healthy food choices,
while patients in LMIC on the other hand were more likely to
report lack of health care facilities [25]. In terms of acceptability,
LMIC [25] reported barriers similar to those reported by ethnic
minorities in HIC [30,41].
Among quantitative studies that provided enough data to pool
the prevalence of patient barriers, only seven were from LMIC; 2
from South Africa [64,68], and one from each of Malaysia [67],
Egypt [59], Singapore [81], Trinidad [60], and India [76]. Only
one study assessed barriers to screening [69], two studies assessed
barriers to medical adherence [64,81], and two assessed barriers to
following up with a health care provider [59,81].
Figure 4. Pooled prevalence (%) and 95%CI of patient level barriers to hypertension management organized by Michie et al
framework (n=32).
doi:10.1371/journal.pone.0084238.g004
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Discussion
Summary of evidence
Among qualitative studies, health system barriers, specifically
availability barriers, were most commonly discussed as barriers to
HT management for patients and providers. For providers,
availability barriers included lack of resources and time, and a
high workload. For patients, availability barriers were related to
distance and transportation to primary health care centers and
pharmacies, as well as proximity of physical activity facilities and
grocery stores that sell fresh fruits and vegetables. This was
different from quantitative studies, where researchers focused on
barriers related to knowledge and professional identity/agreement
with guidelines among providers. Among patients, researchers
focused on beliefs about treatment consequences, and side effects
of medications.
Figure 5. Pooled effect of barriers on hypertension treatment adherence/persistence (n=5).
doi:10.1371/journal.pone.0084238.g005
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The prevalence of the various barriers in quantitative studies
varied; this reflects the heterogeneity of study populations and
methodologies of the quantitative studies and, in particular, the
extent to which barriers were sought. However, with these caveats,
it was possible to make some inferences on which barriers were
most prevalent in terms of HT management. Affordability barriers
included insufficient financial reimbursement or incentives to
apply recommended HT care were most common among
providers.
For patients, very few studies assessed barriers to awareness
[screening], likely because such studies require general population
studies which are more difficult to mount than clinic based studies
of HT populations. Knowledge barriers regarding the importance
of HT and BP screening, appear to be the most common barriers
to HT detection [awareness]. Stress, anxiety and depression
barriers were most commonly reported in terms of lifestyle change.
In terms of patient persistence and adherence with HT treatments,
patients mainly reported forgetting to take their medication or
were unsure if they had already taken their medication. Finally,
priority setting for regularly scheduling visits to their healthcare
provider was often reported by patients.
Our review suggests that knowledge barriers were commonly
assessed, yet they were not always the most prevalent barrier.
Similar observations can be made about intervention studies to
improve BP control; a Cochrane review identified 72 clinical trials,
of which 30 assessed education interventions directed either at
patients or providers but they were not effective at improving BP
control [57]. The same review reported that self-monitoring and
appointment reminders may be useful but require further
evaluation [82]. These programs likely affect intention barriers
which, based on our review, require further study. Understanding
these barriers may help develop more effective interventions for
improving blood pressure control.
Previous reviews have identified possible barriers to HT
management [6,83], yet none have done so systematically. These
reviews acknowledge that different factors affect HT control,
whether patient related or provider related. Our review system-
atically reviewed the literature and suggests that barriers are likely
different for different stakeholders, settings and outcomes.
Nevertheless, some commonalities across settings were found,
which should become more meaningful with standardized barrier
assessment methods.
Knowledge translation models suggest that success is more likely
if strategies are informed by and tailored to an assessment of
possible barriers and facilitators [84]. This review provides a
framework to help in this process. The framework also offers a
means for future researchers to present their results in ways that
provide greater conceptual clarity on the nature of interventions,
increasing the chances of designing more effective implementation
interventions and translating evidence into improved HT control
[85].
Limitations
The methodological quality of both qualitative and quantitative
studies was modest. Surveys were rarely validated and their
development was usually not explicitly based on theory or previous
qualitative analyses. Other reviews in the literature of barriers to
medication adherence support these findings [86]. Further, studies
mainly focused on providing prevalence of reported barriers and
very few studies measured how these barriers actually might affect
HT control by assessing measures of association. The majority of
included studies were conducted in higher income countries,
mainly the USA, and thus results may not necessarily be
applicable to other high income countries and lower and middle
income countries. Though the literature acknowledges that poor
HT control is determined not only by patient barriers but also
provider barriers [6], the larger number of patient studies included
in this review indicates that research is still focused on assessing
barriers at the patient level, rather looking at other stakeholders.
Further, included studies focused on treatment and control of HT,
whereby intention barriers seemed understudied, and very few
assessed barriers to HT awareness.
The I2 statistic was high even though pooled proportions were
stratified by study outcome [awareness, lifestyle change, treatment
adherence and following up with providers]. Studies were
heterogeneous in terms of the study population, study setting,
use of theory, and barrier assessment methods and tools. We
pooled prevalence of each barrier primarily for illustration, and
the pooled results should therefore be interpreted with caution.
Considerable heterogeneity has been observed in previous studies
pooling proportions of barriers reflecting the nature of the
underlying research [14]. An additional issue is the need to
understand better the role of context-specific factors relating to the
population and the setting being assessed.
A more systematic way of measuring these barriers, using
standardized and validated methods, is necessary. Very few studies
actually assessed the three main themes of the proposed theoretical
framework, and none incorporated aspects from all 12 subthemes.
Using a theoretical framework to measure all the barriers, with the
same methodology, might provide a more reliable way to compare
the prevalence and clinical importance of these barriers between
different settings.
Implications
To improve HT control, intervention should overcome
capability barriers, intention barriers, and health system barriers.
These barriers should be targeted at the provider and the patient
level. More methodologically rigorous studies that consider all the
different barriers and that include lower income countries are
required in order to improve our confidence in determining the
most important modifiable barriers, to compare them among
regions and populations, and to develop interventions tailored to
different settings and types of patients to improve HT control.
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